Emerging data support the use of glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) in reducing AF recurrence post-CA, particularly in patients with type 2 diabetes and obesity [173]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.